{"id":"W4362586968","doi":"10.1016/s1556-0864(23)00338-6","title":"84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Regeneron Pharmaceuticals; Genentech; F-star Therapeutics; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; G1 Therapeutics; Amgen; LUNGevity Foundation; Mesothelioma Applied Research Foundation","keywords":"Medicine; Internal medicine; Oncology; Complete response; Neoadjuvant therapy; Nivolumab; Gastroenterology; Chemotherapy; Surgery; Cancer; Breast cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001507969,0.0002244097,0.0008939385,0.000333953,0.0001269633,0.00003736899,0.0002871141,0.0002884448,0.0009087629],"category_scores_gemma":[0.0001451978,0.0001754567,0.000427476,0.0004747625,0.0001129713,0.0001825143,0.00004476595,0.0004244555,0.00007868449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004481402,"about_ca_system_score_gemma":0.0006976333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001063061,"about_ca_topic_score_gemma":0.00005805761,"domain_scores_codex":[0.9978496,0.0001188815,0.0009275801,0.0002587761,0.0003521688,0.0004930196],"domain_scores_gemma":[0.9980196,0.0003614454,0.0007896236,0.0003185306,0.0003259027,0.0001849183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.07888693,0.0003521508,0.0008505809,0.0001244747,0.001160905,0.0004479408,0.0008770187,0.00002269663,0.1639142,0.00001986168,0.1847074,0.5686358],"study_design_scores_gemma":[0.01690503,0.005334677,0.01213652,0.0005792655,0.0004001572,0.0007653116,0.0007578203,0.0007343898,0.04829816,0.001382401,0.9123684,0.0003379254],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.967634,0.002125697,0.0008260779,0.02442125,0.002395852,0.0006184009,0.00007771473,0.00008310091,0.001817944],"genre_scores_gemma":[0.9466248,0.006468136,0.01995383,0.009704233,0.004395815,0.00008517082,0.0001988239,0.0002178025,0.01235136],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.727661,"threshold_uncertainty_score":0.9950317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0344534782357647,"score_gpt":0.4077052869778547,"score_spread":0.37325180874209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}